MASARYKOVA UNIVERZITA

Design sekvence PCR primerů

Hana Konečná

CEITEC - MU

Centrální laboratoř - Proteomika

Tento projekt je spolufinancován Evropským sociálním fondem a státním rozpočtem České republiky.

EVROPSKÁ UNIE esf

MINISTERSTVO ŠKOLSTVÍ, MLÁDEŽE A TĚLOVÝCHOVY

OP Vzdělávání pro konkurenceschopnost

INVESTICE DO ROZVOJE VZDĚLÁVÁNÍ

MASARYKOVA UNIVERZITA

OLIGONUKLEOTIDY

- definice
- aplikace
- modifikace
- syntéza
- purifikace
- kontrola kvality

- design sekvence
- zásady navrhování
- software OLIGO 7
- praktická ukázka

Tento projekt je spolufinancován Evropským sociálním fondem a státním rozpočtem České republiky.

EVROPSKÁ UNIE esf

MINISTERSTVO ŠKOLSTVÍ, MLÁDEŽE A TĚLOVÝCHOVY

OP Vzdělávání pro konkurenceschopnost

INVESTICE DO ROZVOJE VZDĚLÁVÁNÍ

orientace! polymeráza!

oligonukleotid

- krátká jednořetězcová struktura
- DNA nebo RNA (event. PNA)
- **hydroxyl** na obou koncích (normálně na 5´- konci fosfát)





Aplikace syntetických oligonukleotidů

- primery pro syntézu komplementární DNA
  PCR, Real-Time PCR
- syntéza genů a rekombinantní proteiny
- hybridizační sondy pro klonování
- místně cílená mutageneza
- sekvenování a genetické profilování
- diagnostika – testy a biosensory
- gene arrays
- blokace genové exprese *antisense oligo*
- potenciální léčiva a DNA vakcíny
- NMR studia interakcí DNA-protein
- strukturální rentgenová analýza NA

Modifikace

- degenerace
- konce řetězce
- báze
- fosfát
- cukr
- PNA



Degenerované oligonukleotidy

Příklady:

ACG TAC GTA CGT ACG TAC	nedegenerovaný
ACG TA**M** GTA CGT ACG TAC	M = A/C
ACG TAC GTA C**D**T ACG TAC	D = A/G/T
ACG TAC GTA CGT ACG **N**AC	N = A/C/G/T

Degenerované oligonukleotidy

2-deoxyinosin

M	A or C
R	A or G
W	A or T
S	C or G
Y	C or T
K	G or T
V	A or C or G
H	A or C or T
D	A or G or T
B	C or G or T
N	G or A or T or C
X	G or A or T or C

Modifikace na 5´- konci

postsyntetické modifikace →

sekvenování →
fragmentační analýza
gene arrays
Real-Time PCR

5´
fosforylace
aminoskupina
thioskupina
digoxigenin
biotin
enzymy
psoralen
akridin
cholesterol
fluoresc. barviva
zhášedla
2,4-dinitrofenyl
TBR-chelát
spacer
větvení
blokáda

Modifikace na 3´- konci

derivatizovaná matrice



Real-Time PCR

- 2x značená sonda
- REPORTER
- QUENCHER



2. **Strand displacement:** When the probe is intact, the reporter dye emission is quenched.



3. **Cleavage:** During each extension cycle, the DNA polymerase cleaves the reporter dye from the probe.



4. **Polymerization completed:** Once separated from the quencher, the reporter dye emits its characteristic fluorescence.



Další modifikace

fosforothioáty
fosforodithioáty
H-fosfonáty
metylfosfonáty

← páteř

cukr →

modifikace v 2´pozici
modifikace ribózové jednotky

Terapeutika

→ nedegradována nukleázami!
modifikace fosfodiesterové vazby



ANTISENSE oligonukleotid

- oligonukleotid nebo analog
- komplementární k segmentu RNA nebo DNA
- vazbou inhibuje jejich normální funkci



RNA
s katalytickou
aktivitou

Peptidonukleová kyselina PNA

- nenabitá molekula
- vazba k DNA/RNA

N-(2-aminoethyl)-glycin →



DNA

Peptidonukleová kyselina

- nenabitá molekula
- vazba k DNA/RNA

N-(2-aminoethyl)-glycin →



Vlastnosti PNA

- vysoká termostabilita
- T_m nezávisí na obsahu solí
- vyšší specificita
- vyšší afinita
- rezistentní k enzymům...

Gambari R. *Expert Opin Ther Pat*. 2014, 24(3):267-94.
Peptide nucleic acids: a review on recent patents and technology transfer.

LNA



Locked **N**ucleic **A**cid

2'-O, 4'-C methylenový můstek
potlačená flexibilita ribofuranózového kruhu
struktura je zamčena do rigidní C3-endo konformace
zlepšená hybridizace
výjímečná biostabilita

Molecular Therapy (2012); **20** 8, 1590–1598.
LNA-based Oligonucleotide Electrotransfer for miRNA Inhibition

OLIGONUKLEOTIDY

design

syntéza

purifikace

EXPEDITE 8909

Syntéza oligonukleotidu

- syntéza na pevné fázi
- od 3´-konce k 5´-konci
- bezvodé prostředí



Kontrola kvality



- HPLC
- Perfúzní chromatografie

- anex
- RP

Perfúzní chromatografie

klasický sorbent POROS





Maldi-TOF MS CE



VÝTĚŽEK



PAGE



PURIFIKACE

- Sephadex
- RP cartridge
- HPLC



DESIGN OLIGONUKLEOTIDU

- manuální
- počítačový

www.protocol-online.org/prot/Research_Tools/Online_Tools/Oligo_Design/index.html

Hlavní kritéria pro sekvenci PCR primeru

- vysoce specifické
- netvoří dimery a vlásenky
- stabilní duplexy s aktivní sekvencí
- nepříliš stabilní 3´-konec

OLIGO 6

- PCR primery,
- hybridizační sondy
- sekvenační primery

OLIGO 7 (od roku 2008)

- TaqMan sondy
- primery pro *nested PCR*
- *molecular beacons*
- siRNA

Terminologie PCR primerů

forward primer… část sekvence + vlákna

reverse primer… část sekvence - vlákna



Terminologie

forward primer… část sekvence + vlákna

reverse primer… část sekvence - vlákna



Nasedání PCR primerů



5´ CTT CTG CTC AAT CTT TCT AC 3´ **FORWARD**

+ 5´

```
   1 ATGGCTTCTG CTCAATCTTT CTACAACCAA AGCTCTGTCT TGAAAATCAA
  51 TGTCATGGTT GTGGACGATG ATCATGTTTT CCTTGATATC ATGTCACGCA
 101 TGCTTCAACA CTCCAAATAC AGAGGTAATT AAATATTATT ATCATATTAT
 151 ATATAATATG TTATTGATTT TTTGTTTGTG ATTTCATTTA GATTTTTATT
 201 TCTATGATTT CTTAGCATGA AATACAATTT TTGGAGAAAC AACTAGCAGT
 251 TTTAAAAACA AAACTTGAAT TTTGAGAAAT TCAAAGATGT TATATATATA
 301 TGTCAAAATT TAACAATTAT TCTTCTAAAT CATCCGGATT CCGTTTACAT
 351 GTACACATCT ACAATTTTCA ATTGAGGTAT TCTTGTTTTG ATGCCTTTGA
 401 GACGAATAGT TTGATTGATA AAAAAAATTC TAACCAATAT GATATATAAA
 451 GTTTATTTTC TTTTTGTCAA ACCATACTTT ATACTATGTA ACTTTTTTAA
 501 GAGATTATTG AAAATAGTTT ATTTATAAAA TAGTAACCTA TTGTTGAATT
 551 AAAAAAAAAA AAAAAATTGT AAATCGTGTT TGCAAACGAC ATGTGATTTA
 601 TCTTAGTTTA AAACTAGCTG ATATTCTTCA AATCGACTGT TCTTATAAGT
 651 AATCAACCAA TTAGCATCAA TCACAATAAA TTGTAAACAC TTCAATGAAA
 701 ATGGTGATTT TAAAGAATAT GTTTTACTTA TGTTATGAAC TATCTCAAAT
 751 TTGTGAAATA TTTCATAACT AATGTGGAAA ACTATATAAC CCCTCCATAC
 801 AAAACGTAAG TAAAATTTAT GAAATCCTAT CATTTTTAAA GGTTAAACCA
 851 ATCAAAAAGT AATAATTCTT GGTACTTGCA ATATTTTTGT CATTATATTT
 901 TAGTTTATTA ATTTTATTTT GATTAAATGG TTTTAGATCC ATCAGTTATG
 951 GAGATCGCAG TTATAGCTGT AGACGATCCG AAGAAAGCAT TATCTACTCT
1001 AAAAATTCAA CGAGACAATA TAGATCTCAT AATCACAGAT TATTATATGC
1051 CTGGTATGAA CGGTTTACAA CTCAAAAAAC AAATCACTCA GGAATTTGGA
1101 AATTTACCGG TCTTAGGTAA CATTTTTTGT TCTTTACAAC TTAAATTAAA
```

3´

5´ TGA AGA ATA TCA GCT AGT TT 3´ **REVERSE**


Sequence
File: Human 4E.seq
DNA Sequence
Sequence Length: 1868 nt
Reading Frame: +1
Current Oligo Length: 21 nt
Position: 356
t_m: 59.3°C
Selected Oligo | Position | Length
Forward Primer | 259 | 18
Reverse Primer | 328 | 18
Upper Oligo | --- | ---
Lower Oligo | 294 | 22
PCR Product | 87 nt
| Feature | Location
1 | source | -18..1850
2 | CDS | 1..651
pos: 350
tm: 57.1
CCTGGCTGTGACTACTCA
TTAATGCCTGGCTGTGACTACTCACTTTTTAAGGATGGTATTGAGCCTATGTGGGAAGATGAGAAAAACAAACGGGGAGGACGATGGCTAATTACATTGAACAAACAGCAGAGACGAAGTGACCTC
AATTACGGACCGACACTGATGAGTGAAAAATTCCTACCATAACTCGGATACACCCTTCTACTCTTTTTGTTTGCCCCTCCTGCTACCGATTAATGTAACTTGTTTGTCGTCTCTGCTTCACTGGAG
ACTCGGATACACCCTTCTACTC
CCTCCTGCTACCGATTAA
L M P G C D Y S L F K D G I E P M W E D E K N K R G G R W L I T L N K Q Q R R S D L


Search for Primers & Probes
Search Options
Subsearches
Search in:
+ Strand
– Strand
Search Mode:
Select
Verify
Complex Substrate
PCR Primers
Compatible with the
Forward Primer
Reverse Primer
TaqMan Probes & PCR Pairs
Compatible with the
Upper Probe
Lower Probe
Molecular Beacons & PCR Pairs
Nested Primers
Sequencing Primers
Hybridization Probes
siRNA Probes
After successfull search show:
All Results
Search
Cancel
Apply
Parameters
Ranges
Defaults


Search for Primers & Probes
Search Options
Subsearches
Search method: Compatible Pairs
Eliminate Ambiguous Bases
Duplex-free Oligonucleotides
Highly Specific Oligonucleotides (3'-end Stability)
5'-end Stability
siRNA Internal Stability
Oligonucleotides with GC Clamp
Oligonucleotides within Selected Tm Limits
Hairpin-free Oligonucleotides
Eliminate Mono- and Di-Nucleotide Repeats
Detect Sequence Repeats
Eliminate Frequent Oligonucleotides
Omit High Secondary Structure Regions in the Template
Check Primers/Probe Sequence Constraints
Restrict the Number of G Bases
Eliminate False Priming Oligonucleotides
and Continue Above Search in Other File(s)
Consensus Primers
Search
Cancel
Apply
Parameters
Ranges
Defaults

PCR

File: Human 4E.seq



Optimal Annealing Temperature: 50.8 °C (Max: 66.3 °C)

	Position and Length		T_m [°C]	GC [%]	P.E.#	Score
Product	862		78.9	29.6	n/a	697
Forward Primer	918	22	56.9	45.5	471 / 471	840
Reverse Primer	1753	27	55.3	29.6	489 / 489	834
Upper Oligo	979	24	56.5	33.3	479 / 479	917
Lower Oligo	1694	23	55.4	39.1	457 / 457	841

Product T_m – Reverse Primer T_m: 23.6 °C

Primers T_m difference: 1.6 °C

Comments:

	Concentration	
Forward Primer	200.0	nM
Reverse Primer	200.0	nM
Upper Oligo	200.0	nM
Lower Oligo	200.0	nM
Monovalent Cation	50.0	mM
Free Mg[2+]	0.7	mM

Total Na[+] Equivalent: 155.8 mM



Priming Efficiency PE Score

- **HAIRPIN intramolekulární**
- **DIMER intermolekulární**




Current Oligo Hairpin Stems
File: BRCA2 gene.seq
Current Oligo 21-mer [5042]
1. # of paired bases = 5; loop = 5 nt; ΔG = -3.0 kcal/mol; Tm = 54.6 °C
5042 GAATT 5046
5056 CTTAA 5052
5'GAATTAG
A
3'ATTAAACTTAAAT
2. # of paired bases = 6; loop = 5 nt; ΔG = 0.2 kcal/mol; Tm = 21.7 °C
5043 AATTAGA 5049
5061 TTAAACT 5055
5'GAATTAGATA
A
3'ATTAAACTTA
3. # of paired bases = 4; loop = 2 nt; ΔG = 0.9 kcal/mol; Tm = 8.7 °C
5052 AATT 5055
5061 TTAA 5058
5'GAATTAGATAAATTC
3'ATTAAA


Reverse Primer False Priming Sites
File: M13MP18
Reverse Primer M13MP18:6310R19 (positive strand)
Priming efficiency of the perfect match is 482 (above the threshold)
Priming efficiency: 482 (above the threshold)
5'(6328) GGTTTTCCCAGTCACGACG (6310)3'
3'(6328) ccaaaagggtcagtgctgc (6310)5'
Priming efficiency: 244 (above the threshold)
5'(6328) GGTTTTCCCAGTCACGACG (6310)3'
3'(626) agcaaatggtc--tgctgc (610)5'
Priming efficiency: 193 (above the threshold)
5'(6328) GGTTTTCCCAGTCACGACG (6310)3'
3'(5125) tctaagtggtcagtg-tgc (5108)5'


Forward Primer Composition
File: BRCA2 gene.seq
Forward Primer AY436640:6275F19
T_d 64.2° [nearest neighbor method]
T_m 56.5° [nearest neighbor method]
T_m 70.8° [%GC method]
T_m 56° [2(A+T)° + 4(G+C)° method]
T_m (RNA)[1M Na] 81° [%GC method]
T_m (DNA:RNA)[1M Na] 74.7° [%GC method]
A_{260}/A_{280} 1.59 [single strand]
Molecular Weight 5.8K [one strand]
Molecular Weight 11.7K [two strands]
µg/OD 47.4 [dsDNA]
Base Number & %
A 2 [10.5%]
C 5 [26.3%]
G 4 [21.1%]
T 8 [42.1%]
A + T 10 [52.6%]
G + C 9 [47.4%]



#	Date	ID Number	Sequence	3'-Dim. ΔG		P.E. / p.e.		Tm / t_m	
21	12/02/06	AY436640:5916R19	AATGCCTGCCTTTAGTCTG	-	SC	430	430	54.1	54.5
22	12/02/06	AY436640:5916R20	CAATGCCTGCCTCTAGTCTG	0.3	SC	366	450	50.9	57.2
23	12/02/06	AY436640:5937R21	TCAATTTCTTTAGCTTGGCAT	0.3	SC	449	449	54.7	53.1
24	12/02/06	AY436640:5937R22	TTCAATTTCTTTAGCTTGGCAT			458	458	55.9	53.8
25	12/02/06	AY436640:4695U22	TGCCTTAACAAAAGTAATCCAT	0.3	SC	432	432	54.5	53.0
26	12/02/06	AY436640:5325U22	AATTACGTCTTTCTTATGCCAA	0.3	SC	453	453	53.3	53.0
27	12/02/06	AY436640:5786L23	CTCTGCCTAGAACATTATCACTC	-0.3	SC	451	451	54.8	55.0
28	12/02/06	AY436640:5860L19	AACAACCAAAGCCAACCTG	-0.9	SC	444	444	55.3	55.9

#	Forward Primer (1)	Reverse Primer (2)	Upper Oligo (3)	Lower Oligo (4)
36	8	23	25	28
42	8	24	25	28
47	9	14	25	27
39	9	15	25	27
33	9	16	25	27
61	9	17	25	27
48	9	18	25	27


Restriction Enzyme Sites in Protein
File: BRCA2 gene.seq
22400 22600 22800 23000 23200 23400 23600 23800 24000 24200 24400 24600 24800 25000 25200 25400 25600 25800 26000 26200 26400 26600 26800
33 EcoRI
34 EcoRV
35 EsP3I
36 FseI
37 FspI
38 GsuI
39 HindIII
40 HpaI
41 KpnI
42 MluI
43 MunI
44 NaeI
45 NarI
46 NcoI
47 NdeI
Enzyme Site # Cuts Positions & Fragment Sizes
41 KpnI GT2VpzY6 8 21253 23654 68 23722 52 23774 237 24011 585 24596 162 24758
629 25387 1219 26606 22851
42 MluI TR1RVyA7 5 22233 22674 2824 25498 576 26074 106 26180 244 26424 23033
43 MunI QL3NawI5 10 21287 23620 355 23975 351 24326 282 24608 242 24850 72 24922
351 25273 714 25987 187 26174 420 26594 22863
44 NaeI AG2PAxR6 7 21823 23084 597 23681 1286 24967 86 25053 573 25626 149 25775
623 26398 23059
45 NarI GA2APzR6 1 20043 24864 24593
46 NcoI PW3HGwM5 4 22361 22546 336 22882 887 23769 531 24300 25157
47 NdeI HM2IawY5 2 20366 24541 1211 25752 23705
48 NheI AS2LAx-6 16 22276 22631 322 22953 185 23138 88 23226 27 23253 461 23714
369 24083 312 24395 288 24683 151 24834 273 25107 536 25643
402 26045 30 26075 210 26285 372 26657 22800
Search: 22454 to 27004 End Cut Type: Blunt, Odd, 3'-overhang, 5'-overhang


Hybridization Time
File: M13MP18
DNA Length:
21
nt.
Concentration:
200.0
nM
1.298
µg/mL
T½ = 45.4 sec
T = 3 min 47 sec


Concentrations
File: BRCA2 gene.seq
Constant Concentration
Constant Volume
Current +Oligo: 5.08 nmol/OD, 32.5 µg/OD
Current -Oligo: 4.67 nmol/OD, 30.9 µg/OD
Entire Sequence (ds): 0.001 nmol/OD, 48.1 µg/OD
Forward Primer: 5.98 nmol/OD, 35.0 µg/OD
Reverse Primer: 5.31 nmol/OD, 34.0 µg/OD
PCR Product (ds): 0.146 nmol/OD, 48.1 µg/OD
Upper Oligo: 4.83 nmol/OD, 31.2 µg/OD
Lower Oligo: 4.67 nmol/OD, 30.9 µg/OD
32.5 µg
or 1.0 OD(260)
or 5.084 nmol
in 508.4 µL
yields 10.0 µM

AHP2 cDNA (TAIR database)

Sequence: AT3G29350.1 Date last modified 2007-04-17 Name AT3G29350.1 Tair Accession Sequence:4010737427 Sequence Length (bp) 827

1 ACAATTCGCG AGAAAGACAA AACACAAGTT TCTTCTTCTT GGGATTGGCT
51 ATTTCCAGAA ATCCAAGTCA ATAATCAAAG TCCAAACAAA AAAATCCTCT
101 CCCAATCTCC GCTTCACTCT TCTC**ATG**GAC GCTCTCATTG CTCAGCTTCA
151 GAGACAATTT CGTGATTACA CCATTTCTCT CTACCAACAG GGGTTTTTGG
201 ATGATCAATT TACTGAGTTG AAAAAGCTAC AAGATGATGG AAGTCCTGAT
251 TTTGTGTCTG AAGTGCTTTC ACTTTTCTTT GAAGATTGTG TGAAGCTTAT
301 CAGTAACATG GCTAGAGCTT TGGACACGAC AGGAACTGTA GATTTTAGTC
351 AGGTAGGTGC TAGTGTGCAT CAATTGAAGG GTAGTAGCTC AAGTGTTGGT
401 GCCAAGAGGG TCAAAACTTT GTGTGTTAGC TTCAAGGAAT GTTGTGAAGC
451 TAAGAACTAC GAAGGGTGTG TGAGATGTTT GCAGCAAGTG GATATTGAGT
501 ACAAGGCGTT AAAGACAAAG CTTCAAGATA TGTTCAATCT TGAGAAACAG
551 ATCATTCAAG CTGGTGGTAT AGTTCCTCAA GTGGATATTA AC**TAA**AGAGA
601 CTAGTCCATA AGAAGAAAAA AGATGATGAC TTTCTTTCTT TAGTTTCTCT
651 TCTAAATTAT TTTGGATTTG GTGTTTGCTC AAAAACTCAA TAAAATATGT
701 GCAAAAAGAA ACAAAAACAA GTGATGGTTG TTTATAAATC AGTAGTATGT
751 ATTGTTTGAT CTCATCCGAG AAAATTGAAA CCATTGGACT AATGAATGTG
801 ATGATAATAT ATATTGGTTT GCTTCTG

101 CCCAATCTCC GCTTCACTCT TCTC**ATG**GAC GCTCTCATTG CTCAGCTTCA
151 GAGACAATTT CGTGATTACA CCATTTCTCT CTACCAACAG GGGTTTTTGG
201 ATGATCAATT TACTGAGTTG AAAAAGCTAC AAGATGATGG AAGTCCTGAT
251 TTTGTGTCTG AAGTGCTTTC ACTTTTCTTT GAAGATTGTG TGAAGCTTAT
301 CAGTAACATG GCTAGAGCTT TGGACACGAC AGGAACTGTA GATTTTAGTC
351 AGGTAGGTGC TAGTGTGCAT CAATTGAAGG GTAGTAGCTC AAGTGTTGGT
401 GCCAAGAGGG TCAAAACTTT GTGTGTTAGC TTCAAGGAAT GTTGTGAAGC
451 TAAGAACTAC GAAGGGTGTG TGAGATGTTT GCAGCAAGTG GATATTGAGT
501 ACAAGGCGTT AAAGACAAAG CTTCAAGATA TGTTCAATCT TGAGAAACAG
551 ATCATTCAAG CTGGTGGTAT AGTTCCTCAA GTGGATATTA AC**TAA**AGAGA

EcoRI restriction site

5´……G| AATTC……3´
3¨……CTTAA| G……5´

Design of primers

AHP2ex_up

5'- CCG GAA TTC ATG GAC GCT CTC ATT GCT CAG – 3'

AHP2ex_low

5'- CCG GAA TTC TTA GTT AAT ATC CAC TTG AGG – 3'

101 CCCAATCTCC GCTTCACTCT TCTC**ATG**GAC GCTCTCATTG CTCAGCTTCA
151 GAGACAATTT CGTGATTACA CCATTTCTCT CTACCAACAG GGGTTTTTGG
201 ATGATCAATT TACTGAGTTG AAAAAGCTAC AAGATGATGG AAGTCCTGAT
251 TTTGTGTCTG AAGTGCTTTC ACTTTTCTTT GAAGATTGTG TGAAGCTTAT
301 CAGTAACATG GCTAGAGCTT TGGACACGAC AGGAACTGTA GATTTTAGTC
351 AGGTAGGTGC TAGTGTGCAT CAATTGAAGG GTAGTAGCTC AAGTGTTGGT
401 GCCAAGAGGG TCAAAACTTT GTGTGTTAGC TTCAAGGAAT GTTGTGAAGC
451 TAAGAACTAC GAAGGGTGTG TGAGATGTTT GCAGCAAGTG GATATTGAGT
501 ACAAGGCGTT AAAGACAAAG CTTCAAGATA TGTTCAATCT TGAGAAACAG
551 ATCATTCAAG CTGGTGGTAT AGTT**CCTCAA** GTGGATATTA ACT**AA**AGAGA

EcoRI restriction site

5´……G| AATTC……3´
3¨……CTTAA| G……5´

Design of primers

AHP2ex_up

5’- CCG GAA TTC ATG GAC GCT CTC ATT GCT CAG – 3’

AHP2ex_low

5’- CCG GAA TTC TTA GTT AAT ATC CAC TTG AGG – 3’

LITERATURA

- Artificial DNA: Methods and Applications; Khudyakov, Y.E., Fields, W.A., Ed. (2003)
- PCR Primer: A Laboratory Manual (2003)
- OLIGO Primer analysis software, Version 7
- *Expert Opin Ther Pat.* 2014, 24(7):801-19. Oligonucleotide delivery: a patent review (2010 - 2013).
- *AAPS Journal* 2009, 11(1): 195 - 203. Targeted Delivery Systems for Oligonucleotide Therapeutics
- Large-scale de novo DNA synthesis: technologies and applications Nature Methods 2014, 11 (5): 499

Discovery is not in seeking new landscapes, but in having new eyes…

Marcel Proust

Tato prezentace vznikla s podporou projektu **OP VK** „*Rozvoj týmu pro výuku, výzkum a aplikace v oblasti funkční genomiky a proteomiky*“(CZ.1.07/2.3.00/09.0132)
Tento projekt je spolufinancován Evropským sociálním fondem a státním rozpočtem České republiky.

INVESTICE DO ROZVOJE VZDĚLÁVÁNÍ